



**SERES**  
THERAPEUTICS™

## Seres Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference

March 2, 2017

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2017-- Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced it will present at the Cowen and Company 37<sup>th</sup> Annual Health Care Conference in Boston, MA on Wednesday, March 8 at 11:20 a.m. ET.

Live audio webcast of the presentation be available under the "Investors and Media" section of Seres' website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.

### About Seres Therapeutics

Seres Therapeutics, Inc. is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced. The Phase 2 study of Seres' program SER-109 has been completed in multiply recurrent *C. difficile* infection. Seres' second clinical candidate, SER-287, is being evaluated in a Phase 1b study in patients with mild-to-moderate ulcerative colitis (UC). Seres is also developing SER-262, the first ever synthetic microbiome therapeutic candidate, in a Phase 1b study in patients with primary *C. difficile* infection. For more information, please visit [www.serestherapeutics.com](http://www.serestherapeutics.com). Follow us on Twitter @SeresTx.



View source version on businesswire.com: <http://www.businesswire.com/news/home/20170302005208/en/>

Source: Seres Therapeutics Inc.

### IR or PR Contact:

Seres Therapeutics  
Carlo Tanzi, Ph.D., 617-203-3467  
Head of Investor Relations and Corporate Communications  
[Ctanzi@serestherapeutics.com](mailto:Ctanzi@serestherapeutics.com)